Global Periodontal Therapeutics Market - 2025-2033
Overview
The global periodontal therapeutics market reached US$ 1,005.93 million in 2024 and is expected to reach US$ 1,950.35 million by 2033, growing at a CAGR of 7.2 % during the forecast period of 2025-2033.
The global periodontal therapeutics market encompasses a range of products and treatments specifically designed to manage periodontal diseases, which are infections that affect the supporting structures of the teeth, including the gums, periodontal ligament, and alveolar bone. These diseases primarily manifest as gingivitis and periodontitis, both of which can lead to significant oral health complications if not addressed.
Gingivitis is a common and mild form of gum disease characterized by inflammation of the gums. It often presents as redness, swelling, and bleeding, particularly during brushing or flossing. On the other hand, periodontitis is a more severe form of gum disease that develops when gingivitis is left untreated.
Market Dynamics: Drivers & Restraints
Rising Prevalence of Periodontal Diseases
The rising prevalence of periodontal diseases is a significant driver in the global periodontal therapeutics market. Periodontal diseases, which include a variety of inflammatory conditions that impact the supporting structures of the teeth, have seen a notable increase in prevalence worldwide.
Factors such as increasing awareness of oral health, a growing geriatric population, and advancements in dental technology are driving the expansion of the periodontal therapeutics market. Furthermore, key players in the industry are implementing strategies such as partnerships and collaborations that would drive this market growth. For instance, in May 2023, OraPharma announced a strategic partnership with Alex Rodriguez, a renowned sports figure and health advocate, to enhance awareness about the importance of managing gum disease. This collaboration is part of the Cover Your Bases campaign, which aims to educate the public, particularly within the Hispanic community, about the prevalence and implications of gum disease.
Lack of Awareness among People
The lack of awareness and education regarding periodontal diseases significantly constrains the global periodontal therapeutics market. Despite some progress in raising awareness about oral health, many individuals remain uninformed about the signs, symptoms, and consequences of periodontal diseases.
Research indicates that a substantial portion of the population lacks basic knowledge about the etiology of these conditions, which can lead to delayed diagnosis and treatment. For instance, a systematic review highlighted that poor awareness is frequently cited as a primary reason for treatment failure within communities.
The lack of awareness directly affects individuals' willingness to seek treatment. Many people may underestimate the importance of regular dental check-ups or fail to recognize early signs of gum disease, leading to a higher prevalence of untreated conditions. For instance, a study found that low awareness was associated with fewer perceived periodontal health issues, and that individuals might not prioritize dental visits if they do not understand the risks involved.
Segment Analysis
The global periodontal therapeutics market is segmented based on disease type, drug type, route of administration, and region.
Disease Type:
The gingivitis segment in disease type is expected to dominate the global periodontal therapeutics market with the highest market share
Gingivitis, the mildest form of periodontal disease, is primarily caused by plaque accumulation on the teeth and gums, leading to inflammation, redness, swelling, and occasional bleeding. While generally reversible with professional treatment and good oral hygiene, untreated gingivitis can progress to periodontitis, making early intervention critical.
The rising awareness of oral health, growing emphasis on preventive care, and the increasing availability of over-the-counter and prescription therapeutics are driving demand in this segment. Topical antimicrobials, antiseptic mouth rinses, and enzyme suppressants are commonly used to treat gingivitis, and their market demand is supported by continuous product innovation.
Additionally, public health campaigns, dental screening programs, and school-based oral care initiatives further contribute to the segment’s growth by promoting early diagnosis and treatment. As oral hygiene becomes more closely associated with overall systemic health, the gingivitis segment is expected to expand steadily, particularly in emerging markets where improvements in dental care infrastructure are underway. These factors have solidified the segment's position in the global periodontal therapeutics market.
Geographical Analysis
North America is expected to hold a significant position in the global periodontal therapeutics market with the highest market share
The region’s dominance is largely attributed to the high prevalence of periodontal diseases, especially among the aging population, and the widespread adoption of advanced therapeutic solutions. According to the CDC, nearly half of adults over 30 in the U.S. suffer from some form of periodontal disease, creating a substantial demand for effective treatment modalities.
A substantial portion of the adult population in North America is affected by periodontal diseases. In the United States, approximately 42% of adults aged 30 years and older suffer from periodontitis, highlighting a significant demand for effective therapeutic interventions.
The region's aging demographic is more susceptible to periodontal conditions due to factors like systemic health issues and decreased immunity. As people retain their natural teeth longer, the need for periodontal care increases, driving the market for therapeutics that address these age-related oral health challenges.
Innovations in dental technology have introduced advanced treatment options such as local drug delivery systems, laser therapies, and regenerative techniques. These advancements offer more effective, less invasive, and patient-friendly solutions, enhancing treatment outcomes and patient compliance.
North America hosts several leading pharmaceutical and dental companies actively involved in the development and distribution of periodontal therapeutics. Collaborations between research institutions and industry players have led to significant investments in clinical trials and product development, fostering innovation and market growth.
Competitive Landscape
The major global players in the periodontal therapeutics market include Pfizer Inc., Lupin, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Cipla, Advacare, Bausch Health Companies Inc., US Antibiotics, and Melinta Therapeutics, among others.
Key Developments
Target Audience 2024
The global periodontal therapeutics market reached US$ 1,005.93 million in 2024 and is expected to reach US$ 1,950.35 million by 2033, growing at a CAGR of 7.2 % during the forecast period of 2025-2033.
The global periodontal therapeutics market encompasses a range of products and treatments specifically designed to manage periodontal diseases, which are infections that affect the supporting structures of the teeth, including the gums, periodontal ligament, and alveolar bone. These diseases primarily manifest as gingivitis and periodontitis, both of which can lead to significant oral health complications if not addressed.
Gingivitis is a common and mild form of gum disease characterized by inflammation of the gums. It often presents as redness, swelling, and bleeding, particularly during brushing or flossing. On the other hand, periodontitis is a more severe form of gum disease that develops when gingivitis is left untreated.
Market Dynamics: Drivers & Restraints
Rising Prevalence of Periodontal Diseases
The rising prevalence of periodontal diseases is a significant driver in the global periodontal therapeutics market. Periodontal diseases, which include a variety of inflammatory conditions that impact the supporting structures of the teeth, have seen a notable increase in prevalence worldwide.
Factors such as increasing awareness of oral health, a growing geriatric population, and advancements in dental technology are driving the expansion of the periodontal therapeutics market. Furthermore, key players in the industry are implementing strategies such as partnerships and collaborations that would drive this market growth. For instance, in May 2023, OraPharma announced a strategic partnership with Alex Rodriguez, a renowned sports figure and health advocate, to enhance awareness about the importance of managing gum disease. This collaboration is part of the Cover Your Bases campaign, which aims to educate the public, particularly within the Hispanic community, about the prevalence and implications of gum disease.
Lack of Awareness among People
The lack of awareness and education regarding periodontal diseases significantly constrains the global periodontal therapeutics market. Despite some progress in raising awareness about oral health, many individuals remain uninformed about the signs, symptoms, and consequences of periodontal diseases.
Research indicates that a substantial portion of the population lacks basic knowledge about the etiology of these conditions, which can lead to delayed diagnosis and treatment. For instance, a systematic review highlighted that poor awareness is frequently cited as a primary reason for treatment failure within communities.
The lack of awareness directly affects individuals' willingness to seek treatment. Many people may underestimate the importance of regular dental check-ups or fail to recognize early signs of gum disease, leading to a higher prevalence of untreated conditions. For instance, a study found that low awareness was associated with fewer perceived periodontal health issues, and that individuals might not prioritize dental visits if they do not understand the risks involved.
Segment Analysis
The global periodontal therapeutics market is segmented based on disease type, drug type, route of administration, and region.
Disease Type:
The gingivitis segment in disease type is expected to dominate the global periodontal therapeutics market with the highest market share
Gingivitis, the mildest form of periodontal disease, is primarily caused by plaque accumulation on the teeth and gums, leading to inflammation, redness, swelling, and occasional bleeding. While generally reversible with professional treatment and good oral hygiene, untreated gingivitis can progress to periodontitis, making early intervention critical.
The rising awareness of oral health, growing emphasis on preventive care, and the increasing availability of over-the-counter and prescription therapeutics are driving demand in this segment. Topical antimicrobials, antiseptic mouth rinses, and enzyme suppressants are commonly used to treat gingivitis, and their market demand is supported by continuous product innovation.
Additionally, public health campaigns, dental screening programs, and school-based oral care initiatives further contribute to the segment’s growth by promoting early diagnosis and treatment. As oral hygiene becomes more closely associated with overall systemic health, the gingivitis segment is expected to expand steadily, particularly in emerging markets where improvements in dental care infrastructure are underway. These factors have solidified the segment's position in the global periodontal therapeutics market.
Geographical Analysis
North America is expected to hold a significant position in the global periodontal therapeutics market with the highest market share
The region’s dominance is largely attributed to the high prevalence of periodontal diseases, especially among the aging population, and the widespread adoption of advanced therapeutic solutions. According to the CDC, nearly half of adults over 30 in the U.S. suffer from some form of periodontal disease, creating a substantial demand for effective treatment modalities.
A substantial portion of the adult population in North America is affected by periodontal diseases. In the United States, approximately 42% of adults aged 30 years and older suffer from periodontitis, highlighting a significant demand for effective therapeutic interventions.
The region's aging demographic is more susceptible to periodontal conditions due to factors like systemic health issues and decreased immunity. As people retain their natural teeth longer, the need for periodontal care increases, driving the market for therapeutics that address these age-related oral health challenges.
Innovations in dental technology have introduced advanced treatment options such as local drug delivery systems, laser therapies, and regenerative techniques. These advancements offer more effective, less invasive, and patient-friendly solutions, enhancing treatment outcomes and patient compliance.
North America hosts several leading pharmaceutical and dental companies actively involved in the development and distribution of periodontal therapeutics. Collaborations between research institutions and industry players have led to significant investments in clinical trials and product development, fostering innovation and market growth.
Competitive Landscape
The major global players in the periodontal therapeutics market include Pfizer Inc., Lupin, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Cipla, Advacare, Bausch Health Companies Inc., US Antibiotics, and Melinta Therapeutics, among others.
Key Developments
- In April 2025, Convergent Dental introduced the Solea Perioguide, a next-generation laser application designed for minimally invasive periodontal therapy. Building upon the capabilities of its predecessor, Ultraguide, this innovation enables dentists to perform in-pocket laser treatments for moderate to severe periodontitis with enhanced precision and patient comfort.
- In May 2023, OraPharma announced a strategic partnership with Alex Rodriguez, a renowned sports figure and health advocate, to enhance awareness about the importance of managing gum disease. This collaboration is part of the Cover Your Bases campaign, which aims to educate the public, particularly within the Hispanic community, about the prevalence and implications of gum disease.
- Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
- Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
- Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
- Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
- Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
- Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
- Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
- Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
- Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
- Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
- Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
- Post-market Surveillance: Uses post-market data to enhance product safety and access.
- Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
Target Audience 2024
- Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
- Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
- Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
- Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
- Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
- Supply Chain: Distribution and Supply Chain Managers.
- Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
- Academic & Research: Academic Institutions.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Disease Type
2.4. Snippet by Drug Type
2.5. Snippet by Route of Administration
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Periodontal Diseases
3.1.1.2. Technological Advancements in Treatment Modalities
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Lack of Awareness among People
3.1.2.2. High Treatment Costs
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Growth of Tele-Dentistry and Home Care Solutions
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with the largest-selling Brand
4.1.3. Market leaders with established Product
4.2. CXO Perspectives
4.3. Latest Developments and Breakthroughs
4.4. Regulatory and Reimbursement Landscape
4.4.1. North America
4.4.2. Europe
4.4.3. Asia Pacific
4.4.4. South America
4.4.5. Middle East & Africa
4.5. Porter’s Five Forces Analysis
4.6. Supply Chain Analysis
4.7. Patent Analysis
4.8. SWOT Analysis
4.9. Unmet Needs and Gaps
4.10. Recommended Strategies for Market Entry and Expansion
4.11. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.12. Pricing Analysis and Price Dynamics
4.13. Key Opinion Leaders
5. PERIODONTAL THERAPEUTICS MARKET, BY DISEASE TYPE
5.1. Introduction
5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Disease Type
5.1.2. Market Attractiveness Index By Disease Type
5.2. Gingivitis*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Chronic Periodontitis
5.4. Aggressive Periodontitis
5.5. Others
6. PERIODONTAL THERAPEUTICS MARKET, BY DRUG TYPE
6.1. Introduction
6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Drug Type
6.1.2. Market Attractiveness Index By Drug Type
6.2. Doxycycline*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Minocycline
6.4. Metronidazole
6.5. Rapamycin
6.6. Chlorhexidine
6.7. Others
7. PERIODONTAL THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Oral*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Parenteral
8. PERIODONTAL THERAPEUTICS MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. U.K.
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. Brazil
8.4.6.2. Argentina
8.4.6.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. China
8.5.6.2. India
8.5.6.3. Japan
8.5.6.4. South Korea
8.5.6.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
11. PFIZER INC.*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Product Sales
11.1.2.4. Product Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals, etc.
11.1.5. SWOT Analysis
11.2. Lupin
11.3. Teva Pharmaceutical Industries Ltd.
11.4. Sun Pharmaceutical Industries Limited
11.5. Cipla
11.6. Advacare
11.7. Bausch Health Companies Inc.
11.8. USAntibiotics.
11.9. Melinta Therapeutics
LIST NOT EXHAUSTIVE
12. ASSUMPTIONS AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Disease Type
2.4. Snippet by Drug Type
2.5. Snippet by Route of Administration
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Periodontal Diseases
3.1.1.2. Technological Advancements in Treatment Modalities
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Lack of Awareness among People
3.1.2.2. High Treatment Costs
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Growth of Tele-Dentistry and Home Care Solutions
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with the largest-selling Brand
4.1.3. Market leaders with established Product
4.2. CXO Perspectives
4.3. Latest Developments and Breakthroughs
4.4. Regulatory and Reimbursement Landscape
4.4.1. North America
4.4.2. Europe
4.4.3. Asia Pacific
4.4.4. South America
4.4.5. Middle East & Africa
4.5. Porter’s Five Forces Analysis
4.6. Supply Chain Analysis
4.7. Patent Analysis
4.8. SWOT Analysis
4.9. Unmet Needs and Gaps
4.10. Recommended Strategies for Market Entry and Expansion
4.11. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.12. Pricing Analysis and Price Dynamics
4.13. Key Opinion Leaders
5. PERIODONTAL THERAPEUTICS MARKET, BY DISEASE TYPE
5.1. Introduction
5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Disease Type
5.1.2. Market Attractiveness Index By Disease Type
5.2. Gingivitis*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Chronic Periodontitis
5.4. Aggressive Periodontitis
5.5. Others
6. PERIODONTAL THERAPEUTICS MARKET, BY DRUG TYPE
6.1. Introduction
6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Drug Type
6.1.2. Market Attractiveness Index By Drug Type
6.2. Doxycycline*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Minocycline
6.4. Metronidazole
6.5. Rapamycin
6.6. Chlorhexidine
6.7. Others
7. PERIODONTAL THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Oral*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Parenteral
8. PERIODONTAL THERAPEUTICS MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. U.K.
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. Brazil
8.4.6.2. Argentina
8.4.6.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. China
8.5.6.2. India
8.5.6.3. Japan
8.5.6.4. South Korea
8.5.6.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
11. PFIZER INC.*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Product Sales
11.1.2.4. Product Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals, etc.
11.1.5. SWOT Analysis
11.2. Lupin
11.3. Teva Pharmaceutical Industries Ltd.
11.4. Sun Pharmaceutical Industries Limited
11.5. Cipla
11.6. Advacare
11.7. Bausch Health Companies Inc.
11.8. USAntibiotics.
11.9. Melinta Therapeutics
LIST NOT EXHAUSTIVE
12. ASSUMPTIONS AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
LIST OF TABLES
Table 1 Global Periodontal Therapeutics Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Million)
Table 2 Global Periodontal Therapeutics Market Value, By Drug Type, 2025, 2029 & 2033 (US$ Million)
Table 3 Global Periodontal Therapeutics Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Million)
Table 4 Global Periodontal Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 5 Global Periodontal Therapeutics Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Million)
Table 6 Global Periodontal Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 7 Global Periodontal Therapeutics Market Value, By Drug Type, 2025, 2029 & 2033 (US$ Million)
Table 8 Global Periodontal Therapeutics Market Value, By Drug Type, 2022-2033 (US$ Million)
Table 9 Global Periodontal Therapeutics Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Million)
Table 10 Global Periodontal Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Million)
Table 11 Global Periodontal Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 12 Global Periodontal Therapeutics Market Value, By Region, 2022-2033 (US$ Million)
Table 13 North America Periodontal Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 14 North America Periodontal Therapeutics Market Value, By Drug Type, 2022-2033 (US$ Million)
Table 15 North America Periodontal Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Million)
Table 16 North America Periodontal Therapeutics Market Value, By Country, 2022-2033 (US$ Million)
Table 17 South America Periodontal Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 18 South America Periodontal Therapeutics Market Value, By Drug Type, 2022-2033 (US$ Million)
Table 19 South America Periodontal Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Million)
Table 20 South America Periodontal Therapeutics Market Value, By Country, 2022-2033 (US$ Million)
Table 21 Europe Periodontal Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 22 Europe Periodontal Therapeutics Market Value, By Drug Type, 2022-2033 (US$ Million)
Table 23 Europe Periodontal Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Million)
Table 24 Europe Periodontal Therapeutics Market Value, By Country, 2022-2033 (US$ Million)
Table 25 Asia-Pacific Periodontal Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 26 Asia-Pacific Periodontal Therapeutics Market Value, By Drug Type, 2022-2033 (US$ Million)
Table 27 Asia-Pacific Periodontal Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Million)
Table 28 Asia-Pacific Periodontal Therapeutics Market Value, By Country, 2022-2033 (US$ Million)
Table 29 Middle East and Africa Periodontal Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 30 Middle East and Africa Periodontal Therapeutics Market Value, By Drug Type, 2022-2033 (US$ Million)
Table 31 Middle East and Africa Periodontal Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Million)
Table 32 Middle East and Africa Periodontal Therapeutics Market Value, By Country, 2022-2033 (US$ Million)
Table 33 Pfizer Inc.: Overview
Table 34 Pfizer Inc.: Product Portfolio
Table 35 Pfizer Inc.: Key Developments
Table 36 Lupin: Overview
Table 37 Lupin: Product Portfolio
Table 38 Lupin: Key Developments
Table 39 Teva Pharmaceutical Industries Ltd.: Overview
Table 40 Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 41 Teva Pharmaceutical Industries Ltd.: Key Developments
Table 42 Sun Pharmaceutical Industries Limited: Overview
Table 43 Sun Pharmaceutical Industries Limited: Product Portfolio
Table 44 Sun Pharmaceutical Industries Limited: Key Developments
Table 45 Cipla: Overview
Table 46 Cipla: Product Portfolio
Table 47 Cipla: Key Developments
Table 48 Advacare: Overview
Table 49 Advacare: Product Portfolio
Table 50 Advacare: Key Developments
Table 51 Bausch Health Companies Inc.: Overview
Table 52 Bausch Health Companies Inc.: Product Portfolio
Table 53 Bausch Health Companies Inc.: Key Developments
Table 54 USAntibiotics. : Overview
Table 55 USAntibiotics. : Product Portfolio
Table 56 USAntibiotics. : Key Developments
Table 57 Melinta Therapeutics: Overview
Table 58 Melinta Therapeutics: Product Portfolio
Table 59 Melinta Therapeutics: Key Developments
Table 1 Global Periodontal Therapeutics Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Million)
Table 2 Global Periodontal Therapeutics Market Value, By Drug Type, 2025, 2029 & 2033 (US$ Million)
Table 3 Global Periodontal Therapeutics Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Million)
Table 4 Global Periodontal Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 5 Global Periodontal Therapeutics Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Million)
Table 6 Global Periodontal Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 7 Global Periodontal Therapeutics Market Value, By Drug Type, 2025, 2029 & 2033 (US$ Million)
Table 8 Global Periodontal Therapeutics Market Value, By Drug Type, 2022-2033 (US$ Million)
Table 9 Global Periodontal Therapeutics Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Million)
Table 10 Global Periodontal Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Million)
Table 11 Global Periodontal Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Million)
Table 12 Global Periodontal Therapeutics Market Value, By Region, 2022-2033 (US$ Million)
Table 13 North America Periodontal Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 14 North America Periodontal Therapeutics Market Value, By Drug Type, 2022-2033 (US$ Million)
Table 15 North America Periodontal Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Million)
Table 16 North America Periodontal Therapeutics Market Value, By Country, 2022-2033 (US$ Million)
Table 17 South America Periodontal Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 18 South America Periodontal Therapeutics Market Value, By Drug Type, 2022-2033 (US$ Million)
Table 19 South America Periodontal Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Million)
Table 20 South America Periodontal Therapeutics Market Value, By Country, 2022-2033 (US$ Million)
Table 21 Europe Periodontal Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 22 Europe Periodontal Therapeutics Market Value, By Drug Type, 2022-2033 (US$ Million)
Table 23 Europe Periodontal Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Million)
Table 24 Europe Periodontal Therapeutics Market Value, By Country, 2022-2033 (US$ Million)
Table 25 Asia-Pacific Periodontal Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 26 Asia-Pacific Periodontal Therapeutics Market Value, By Drug Type, 2022-2033 (US$ Million)
Table 27 Asia-Pacific Periodontal Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Million)
Table 28 Asia-Pacific Periodontal Therapeutics Market Value, By Country, 2022-2033 (US$ Million)
Table 29 Middle East and Africa Periodontal Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Million)
Table 30 Middle East and Africa Periodontal Therapeutics Market Value, By Drug Type, 2022-2033 (US$ Million)
Table 31 Middle East and Africa Periodontal Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Million)
Table 32 Middle East and Africa Periodontal Therapeutics Market Value, By Country, 2022-2033 (US$ Million)
Table 33 Pfizer Inc.: Overview
Table 34 Pfizer Inc.: Product Portfolio
Table 35 Pfizer Inc.: Key Developments
Table 36 Lupin: Overview
Table 37 Lupin: Product Portfolio
Table 38 Lupin: Key Developments
Table 39 Teva Pharmaceutical Industries Ltd.: Overview
Table 40 Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 41 Teva Pharmaceutical Industries Ltd.: Key Developments
Table 42 Sun Pharmaceutical Industries Limited: Overview
Table 43 Sun Pharmaceutical Industries Limited: Product Portfolio
Table 44 Sun Pharmaceutical Industries Limited: Key Developments
Table 45 Cipla: Overview
Table 46 Cipla: Product Portfolio
Table 47 Cipla: Key Developments
Table 48 Advacare: Overview
Table 49 Advacare: Product Portfolio
Table 50 Advacare: Key Developments
Table 51 Bausch Health Companies Inc.: Overview
Table 52 Bausch Health Companies Inc.: Product Portfolio
Table 53 Bausch Health Companies Inc.: Key Developments
Table 54 USAntibiotics. : Overview
Table 55 USAntibiotics. : Product Portfolio
Table 56 USAntibiotics. : Key Developments
Table 57 Melinta Therapeutics: Overview
Table 58 Melinta Therapeutics: Product Portfolio
Table 59 Melinta Therapeutics: Key Developments
LIST OF FIGURES
Figure 1 Global Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 2 Global Periodontal Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 3 Global Periodontal Therapeutics Market Share, By Drug Type, 2024 & 2033 (%)
Figure 4 Global Periodontal Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 5 Global Periodontal Therapeutics Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Periodontal Therapeutics Market Y-o-Y Growth, By Disease Type, 2023-2033 (%)
Figure 7 Gingivitis Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 8 Chronic Periodontitis Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 9 Aggressive Periodontitis Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 10 Others Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 11 Global Periodontal Therapeutics Market Y-o-Y Growth, By Drug Type, 2023-2033 (%)
Figure 12 Doxycycline Drug Type in Global Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 13 Minocycline Drug Type in Global Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 14 Metronidazole Drug Type in Global Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 15 Rapamycin Drug Type in Global Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 16 Chlorhexidine Drug Type in Global Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 17 Others Drug Types in Global Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 18 Global Periodontal Therapeutics Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)
Figure 19 Oral Route of Administration in Global Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 20 Parenteral Route of Administration in Global Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 21 Global Periodontal Therapeutics Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 22 North America Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 23 North America Periodontal Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 24 North America Periodontal Therapeutics Market Share, By Drug Type, 2024 & 2033 (%)
Figure 25 North America Periodontal Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 26 North America Periodontal Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 27 South America Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 28 South America Periodontal Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 29 South America Periodontal Therapeutics Market Share, By Drug Type, 2024 & 2033 (%)
Figure 30 South America Periodontal Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 31 South America Periodontal Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 32 Europe Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 33 Europe Periodontal Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 34 Europe Periodontal Therapeutics Market Share, By Drug Type, 2024 & 2033 (%)
Figure 35 Europe Periodontal Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 36 Europe Periodontal Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 37 Asia-Pacific Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 38 Asia-Pacific Periodontal Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 39 Asia-Pacific Periodontal Therapeutics Market Share, By Drug Type, 2024 & 2033 (%)
Figure 40 Asia-Pacific Periodontal Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 41 Asia-Pacific Periodontal Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 42 Middle East and Africa Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 43 Middle East and Africa Periodontal Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 44 Middle East and Africa Periodontal Therapeutics Market Share, By Drug Type, 2024 & 2033 (%)
Figure 45 Middle East and Africa Periodontal Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 46 Pfizer Inc.: Financials
Figure 47 Lupin: Financials
Figure 48 Teva Pharmaceutical Industries Ltd.: Financials
Figure 49 Sun Pharmaceutical Industries Limited: Financials
Figure 50 Cipla: Financials
Figure 51 Advacare: Financials
Figure 52 Bausch Health Companies Inc.: Financials
Figure 53 USAntibiotics. : Financials
Figure 54 Melinta Therapeutics: Financials
Figure 1 Global Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 2 Global Periodontal Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 3 Global Periodontal Therapeutics Market Share, By Drug Type, 2024 & 2033 (%)
Figure 4 Global Periodontal Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 5 Global Periodontal Therapeutics Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Periodontal Therapeutics Market Y-o-Y Growth, By Disease Type, 2023-2033 (%)
Figure 7 Gingivitis Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 8 Chronic Periodontitis Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 9 Aggressive Periodontitis Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 10 Others Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 11 Global Periodontal Therapeutics Market Y-o-Y Growth, By Drug Type, 2023-2033 (%)
Figure 12 Doxycycline Drug Type in Global Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 13 Minocycline Drug Type in Global Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 14 Metronidazole Drug Type in Global Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 15 Rapamycin Drug Type in Global Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 16 Chlorhexidine Drug Type in Global Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 17 Others Drug Types in Global Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 18 Global Periodontal Therapeutics Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)
Figure 19 Oral Route of Administration in Global Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 20 Parenteral Route of Administration in Global Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 21 Global Periodontal Therapeutics Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 22 North America Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 23 North America Periodontal Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 24 North America Periodontal Therapeutics Market Share, By Drug Type, 2024 & 2033 (%)
Figure 25 North America Periodontal Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 26 North America Periodontal Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 27 South America Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 28 South America Periodontal Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 29 South America Periodontal Therapeutics Market Share, By Drug Type, 2024 & 2033 (%)
Figure 30 South America Periodontal Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 31 South America Periodontal Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 32 Europe Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 33 Europe Periodontal Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 34 Europe Periodontal Therapeutics Market Share, By Drug Type, 2024 & 2033 (%)
Figure 35 Europe Periodontal Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 36 Europe Periodontal Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 37 Asia-Pacific Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 38 Asia-Pacific Periodontal Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 39 Asia-Pacific Periodontal Therapeutics Market Share, By Drug Type, 2024 & 2033 (%)
Figure 40 Asia-Pacific Periodontal Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 41 Asia-Pacific Periodontal Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 42 Middle East and Africa Periodontal Therapeutics Market Value, 2022-2033 (US$ Million)
Figure 43 Middle East and Africa Periodontal Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 44 Middle East and Africa Periodontal Therapeutics Market Share, By Drug Type, 2024 & 2033 (%)
Figure 45 Middle East and Africa Periodontal Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 46 Pfizer Inc.: Financials
Figure 47 Lupin: Financials
Figure 48 Teva Pharmaceutical Industries Ltd.: Financials
Figure 49 Sun Pharmaceutical Industries Limited: Financials
Figure 50 Cipla: Financials
Figure 51 Advacare: Financials
Figure 52 Bausch Health Companies Inc.: Financials
Figure 53 USAntibiotics. : Financials
Figure 54 Melinta Therapeutics: Financials
